Portada Febrero HepatologyHepatology. 2016 Feb;63(2):604-19. doi: 10.1002/hep.28134. Epub 2015 Oct 10


Judit López-Luque, Daniel Caballero-Díaz, Adoración Martinez-Palacián, César Roncero, Joaquim Moreno-Càceres, María García-Bravo, Esther Grueso, Almudena Fernández, Eva Crosas-Molist, María García-Álvaro, Annalisa Addante, Esther Bertran, Angela M. Valverde, Águeda González-Rodríguez, Blanca Herrera, Lluis Montoliu, Teresa Serrano, Jose-Carlos Segovia, Margarita Fernández, Emilio Ramos, Aránzazu Sánchez, Isabel Fabregat.


Different data support a role for the epidermal growth factor receptor (EGFR) pathway during liver regeneration and hepatocarcinogenesis. However, important issues, such as the precise mechanisms mediating its actions and the unique versus redundant functions, have not been fully defined. Here, we present a novel transgenic mouse model expressing a hepatocyte-specific truncated form of human EGFR, which acts as negative dominant mutant (ΔEGFR) and allows definition of its tyrosine kinase-dependent functions. Results indicate a critical role for EGFR catalytic activity during the early stages of liver regeneration. Thus, after two-thirds partial hepatectomy, ΔEGFR livers displayed lower and delayed proliferation and lower activation of proliferative signals, which correlated with overactivation of the transforming growth factor-β pathway. Altered regenerative response was associated with amplification of cytostatic effects of transforming growth factor-β through induction of cell cycle negative regulators. Interestingly, lipid synthesis was severely inhibited in ΔEGFR livers after partial hepatectomy, revealing a new function for EGFR kinase activity as a lipid metabolism regulator in regenerating hepatocytes. In spite of these profound alterations, ΔEGFR livers were able to recover liver mass by overactivating compensatory signals, such as c-Met. Our results also indicate that EGFR catalytic activity is critical in the early preneoplastic stages of the liver because ΔEGFR mice showed a delay in the appearance of diethyl-nitrosamine-induced tumors, which correlated with decreased proliferation and delay in the diethyl-nitrosamine-induced inflammatory process. Conclusion: These studies demonstrate that EGFR catalytic activity is critical during the initial phases of both liver regeneration and carcinogenesis and provide key mechanistic insights into how this kinase acts to regulate liver pathophysiology.


Los grupos de investigación liderados por las doctoras Isabel Fabregat (IDIBELL), y Aránzazu Sánchez (UCM), en colaboración con el CIEMAT y el CSIC, han desarrollado un modelo de ratón modificado genéticamente que permite, por primera vez, estudiar de forma específica en los hepatocitos el papel de la actividad catalítica del receptor del factor de crecimiento epidérmico (EGFR). El trabajo, publicado en la revista Hepatology, demuestra, por un lado, que la activación de la vía del EGFR es crucial durante los primeros estadios de la regeneración hepática tras una hepatectomía parcial, viéndose esta retrasada, con baja activación de señales proliferativas y predominio de los mecanismos citostáticos. Por otro lado, la vía del EGFR juega un papel muy relevante en los estadios primarios de aparición de tumores en el hígado, presentando los ratones transgénicos un retraso en la aparición de prenódulos tras la inyección del carcinógeno dietil-nitrosamina (DEN). Este efecto se correlaciona con una menor inflamación, motor de la aparición de la hepatocarcinogenesis.





El grupo de la doctora Isabel Fabregat, actualmente ubicado en el IDIBELL, empezó en la Universidad Complutense de Madrid, estudiando los mecanismos que controlan la proliferación, diferenciación y muerte de las células del hígado durante el desarrollo y la regeneración hepática. De éste surgió el grupo de la doctora Aránzazu Sánchez, que sigue ubicado en la UCM, manteniendo ambos grupos una estrecha colaboración. Una de sus líneas de investigación se ha enfocado al estudio del papel que juega la vía del receptor del EGF (EGFR) en las células hepáticas, sobretodo en relación a la resistencia a la muerte causada por el factor de crecimiento transformante beta (TGF-β). En este contexto, se diseñó este nuevo modelo animal, que puede contribuir al esclarecimiento de la función de la vía del EGFR en la fisiología y patología del hígado.

Descárgate este artículo aquí.

Did you publish an interesting article recently?

Send it through our application form and we will contact you. Age limit: 32.

The selected articles will participate at the Award to the best article of young people of the SEBBM which will be given during SEBBM conference, that will take place at Spain (free registration, travel and accommodation).

More articles of the month

Sticholysin, Sphingomyelin, and Cholesterol: A Closer Look at a Tripartite Interaction


Actinoporins are a group of soluble toxic proteins that bind to membranes containing sphingomyelin (SM) and oli- gomerize to form pores. Sticholysin II (StnII) is a member of the actinoporin...

Read more

Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour


To satisfy its high energetic demand, the brain depends on the metabolic cooperation of various cell types. For example, astrocytic-derived lactate sustains memory consolidation by serving both as an oxidizable...

Read more

Glucose restriction promotes osteocyte specification by activating a PGC-1α-dependent transcriptional program


Osteocytes, the most abundant of bone cells, differentiate while they remain buried within the bone matrix. This encasement limits their access to nutrients and likely affects their differentiation, a process...

Read more

ParB dynamics and the critical role of the CTD in DNA condensation unveiled by combined force-fluorescence measurements


/Bacillus subtilis/ ParB forms multimeric networks involving non-specific DNA binding leading to DNA condensation. Previously, we found that an excess of the free C-terminal domain (CTD) of ParB impeded DNA...

Read more

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer


Although human epidermal growth factor receptor 2 (HER2)-targeted therapies have dramatically improved the clinical outcome of HER2-positive breast cancer patients, innate and acquired resistance remains an important clinical challenge. New...

Read more

p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton


Planar cell polarity (PCP) and intercellular junctional complexes establish tissue structure and coordinated behaviors across epithelial sheets. In multiciliated ependymal cells, rotational and translational PCP coordinate cilia beating and direct...

Read more

β‐RA reduces DMQ/CoQ ratio and rescues the encephalopathic phenotype in Coq9R239X mice


Coenzyme Q (CoQ) deficiency has been associated with primary defects in the CoQ biosynthetic pathway or to secondary events. In some cases, the exogenous CoQ supplementation has limited efficacy. In...

Read more

Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons


Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons, a process that current therapeutic approaches cannot prevent. In PD, the typical pathological hallmark is the accumulation of...

Read more

Dynamic acetylation of cytosolic phosphoenolpyruvate carboxykinase toggles enzyme activity between gluconeogenic and anaplerotic reactions


Cytosolic phosphoenolpyruvate carboxykinase (PCK1) is considered a gluconeogenic enzyme; however, its metabolic functions and regulatory mechanisms beyond gluconeogenesis are poorly understood. Here, we describe that dynamic acetylation of PCK1 interconverts...

Read more

The Helicase PIF1 Facilitates Resection overSequences Prone to Forming G4 Structures


DNA breaks are complex lesions that can be repaired either by non-homologous end joining (NHEJ) or by homologous recombination (HR). The decision between these two routes of DNA repair is...

Read more

Protector Members